Literature DB >> 1899099

Absence of preferential homologous H/L chain association in hybrid hybridomas.

W B De Lau1, K Heije, J J Neefjes, M Oosterwegel, E Rozemuller, B J Bast.   

Abstract

Bispecific mAb contain two Ag-combining sites each composed of a different combination of H and L chains. The resulting ability to react with and cross-link two different Ag makes these molecules a novel tool for application in biology and medicine. Intact bispecific mAb can be made only by biologic means, e.g., by fusion of two established hybridomas. Appropriate assembly of bispecific mAb by these hybrid cells depends on H = L chain behavior: strong preferential homologous H-L pairing would benefit the yield of bispecific antibodies. We have analyzed the Ig species produced by eight hybrid hybridomas (quadromas). Quadroma-produced IgG was fractionated and characterized for H and L chain content. The Ag reactivities were verified by using ELISA and immunofluorescence. Preferential homologous pairing was seen only with a minority of H-L chain pairs; L chains associated on average in a random fashion with H chains. This indicates that in the B cells from which the parental hybridomas were obtained, no strong selection had occurred on H-L recombination. Our results extend recent biochemical competitive H-L reassociation experiments, where on average an at random association of L chains with H chains was found; evidently this random association occurs in our biologic system as well. For the biologic production of bispecific antibodies this means that only in a small number of cases the "ideal" producer will be met. From the viewpoint of generation of antibody diversity, our results favor a large freedom for combinatorial binding of H and L chains during B cell ontogeny.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.

Authors:  Wolfgang Schaefer; Hans R Völger; Stefan Lorenz; Sabine Imhof-Jung; Jörg T Regula; Christian Klein; Michael Mølhøj
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

2.  A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro.

Authors:  A Fernandez-Sesma; J L Schulman; T M Moran
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

Review 3.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

4.  'In-Format' screening of a novel bispecific antibody format reveals significant potency improvements relative to unformatted molecules.

Authors:  Martin J Scott; Jennifer A Lee; Matthew S Wake; Kelly V Batt; Trevor A Wattam; Ian D Hiles; Thil D Batuwangala; Claire I Ashman; Michael Steward
Journal:  MAbs       Date:  2016-10-27       Impact factor: 5.857

5.  Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia.

Authors:  Emanuela M Ghia; George F Widhopf; Laura Z Rassenti; Thomas J Kipps
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

6.  Receptor editing occurs frequently during normal B cell development.

Authors:  M W Retter; D Nemazee
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

7.  Receptor editing: an approach by autoreactive B cells to escape tolerance.

Authors:  D Gay; T Saunders; S Camper; M Weigert
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

8.  Immunoglobulin (Ig) mu, kappa transgenic mice express transgenic idiotype on endogenously rearranged IgM and IgA molecules by secretion of chimeric molecules.

Authors:  Q Vos; R J Hodes
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

9.  Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

Authors:  R M Luiten; L R Coney; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Authors:  Marie Godar; Virginia Morello; Ava Sadi; Anna Hultberg; Natalie De Jonge; Cristina Basilico; Valérie Hanssens; Michael Saunders; Bart N Lambrecht; Mohamed El Khattabi; Hans de Haard; Paolo Michieli; Christophe Blanchetot
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.